EyePoint Stock Craters 71% After Drug Trial Failure. It May Be an Overreaction.

Duravyu, EyePoint's candidate for wet age-related macular degeneration, misses the mark, but muddled trial data may be to blame.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。